‘Female Viagra’: Not tonight, dear

A Food and Drug Administration advisory panel unanimously rejected a pink pill intended to treat “hypoactive sexual desire disorder."

If you’ve been waiting for a female Viagra, said Katherine Hobson in WSJ.com, “don’t hold your breath.” A Food and Drug Administration advisory panel last week unanimously rejected a pink pill intended to treat “hypoactive sexual desire disorder”—a low sex drive in otherwise healthy, premenopausal women. The drug, flibanserin, led women who took it to have an average of two additional satisfying sexual experiences every month, but the FDA said that success rate wasn’t “particularly compelling,” especially since the subjects reported no noticeable boost in their overall sex drive. The drug maker, German pharmaceutical giant Boehringer Ingelheim, isn’t giving up, said Deborah Kotz in USNews.com. Boehringer claims that low sex drive is a medical condition afflicting “approximately one in 10 women.” If it can produce further research that would convince the FDA that the drug works, and women to take it, the company could rake in billions in sales.

I have so-called low sex drive, said Joan Sewell in TheDailyBeast.com, and I don’t need a cure. This pink pill was created not to make women happier, but to satisfy “the convenient male fantasy of the sexually voracious woman.” Many, or most of us, are not as obsessed with sex as men are—and that doesn’t mean we have a disorder meriting medical intervention. Research shows that most women naturally “have fewer sexual thoughts,” and we are just fine if a few days or weeks pass without a roll in the hay. Strangely, it’s now considered anti-feminist to admit this, since modern, Sex and the City feminists “equate a lower sex drive with inferiority.” There’s nothing inferior about it. When it comes to sex, men and women are just different.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us